On Friday, Taysha Gene Therapies Inc (NASDAQ: TSHA) opened higher 5.47% from the last session, before settling in for the closing price of $2.56. Price fluctuations for TSHA have ranged from $1.05 to $4.32 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 94.30%. Company’s average yearly earnings per share was noted 6.82% at the time writing. With a float of $176.26 million, this company’s outstanding shares have now reached $205.05 million.
Let’s determine the extent of company efficiency that accounts for 73 employees. In terms of profitability, gross margin is 72.63%, operating margin of -1225.78%, and the pretax margin is -1201.08%.
Taysha Gene Therapies Inc (TSHA) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Taysha Gene Therapies Inc is 19.77%, while institutional ownership is 79.38%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares.
Taysha Gene Therapies Inc (TSHA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.89% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Check out the current performance indicators for Taysha Gene Therapies Inc (TSHA). In the past quarter, the stock posted a quick ratio of 5.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 80.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.39 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Looking closely at Taysha Gene Therapies Inc (NASDAQ: TSHA), its last 5-days average volume was 4.14 million, which is a jump from its year-to-date volume of 2.46 million. As of the previous 9 days, the stock’s Stochastic %D was 76.46%. Additionally, its Average True Range was 0.24.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 95.93%, which indicates a significant increase from 93.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 144.86% in the past 14 days, which was higher than the 106.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.75, while its 200-day Moving Average is $1.92. However, in the short run, Taysha Gene Therapies Inc’s stock first resistance to watch stands at $2.79. Second resistance stands at $2.88. The third major resistance level sits at $3.00. If the price goes on to break the first support level at $2.58, it is likely to go to the next support level at $2.46. Should the price break the second support level, the third support level stands at $2.37.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are currently 205,055K shares outstanding in the company with a market cap of 579.59 million. Presently, the company’s annual sales total 8,330 K according to its annual income of -89,300 K. Last quarter, the company’s sales amounted to 2,020 K and its income totaled -18,780 K.
